What is Amnio Technology?
Amnio Technology operates at the intersection of biotechnology and advanced clinical care, specializing in the development and manufacturing of amnion-derived products. By focusing on high-quality, chorion-free allografts, the company effectively addresses the critical need to minimize graft-versus-host autoimmune responses in patients. Their flagship PalinGen brand has become a staple in hospitals and clinics, providing practitioners with reliable, efficacious solutions for complex wound management and orthopedic recovery. Through rigorous adherence to regulatory standards and a commitment to innovation, Amnio Technology has established itself as a trusted partner in the medical community, consistently delivering therapies that target underserved patient populations.
How much funding has Amnio Technology raised?
Amnio Technology has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Amnio Technology
PPP
Public-Private Partnership
What's next for Amnio Technology?
With this latest infusion of capital, Amnio Technology is well-positioned to accelerate its research and development pipeline, potentially introducing next-generation regenerative therapies to the market. The strategic focus will likely shift toward optimizing supply chain efficiencies and expanding the commercial footprint of the PalinGen product line. As the company transitions through this late-stage growth phase, the emphasis remains on scaling production to meet the rising demand for advanced biological grafts. By leveraging its established regulatory framework and clinical trust, Amnio Technology is poised to capture a larger share of the regenerative medicine landscape, setting the stage for long-term sustainability and continued therapeutic breakthroughs in the orthopedic and wound care sectors.
See full Amnio Technology company page
